FRA
ITCI

Front Row Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Front Row Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-97
Closed -$6.64K – 863
2024
Q2 		$6.64K Sell
97
-36
-27% -$2.5K ﹤0.01% 677
2024
Q1 		$9.2K Buy
+133
New +$9.14K ﹤0.01% 611
2023
Q4 		– Sell
-117
Closed -$6.09K – 830
2023
Q3 		$6.09K Buy
117
+9
+8% +$524 ﹤0.01% 626
2023
Q2 		$7K Hold
108
– – ﹤0.01% 612
2023
Q1 		$6K Buy
108
+23
+27% +$1.11K ﹤0.01% 647
2022
Q4 		$4K Hold
85
– – ﹤0.01% 709
2022
Q3 		$4K Buy
+85
New +$4.44K ﹤0.01% 726

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Front Row Advisors's ITCI Position: Q3 2024 in Review

Front Row Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2024, closing a stake of 97 shares — an estimated $6.64K sold.

Front Row Advisors first reported a position in ITCI in Q3 2022 and held it in 7 quarters. The position peaked at $9.2K in Q1 2024. 355 funds tracked by Wall St. Rank hold ITCI as of Q3 2024.

  • Front Row Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2024 after selling out during the quarter.
  • Front Row Advisors sold 97 Intra-Cellular Therapies Inc. shares in Q3 2024, an estimated $6.64K.
  • Front Row Advisors first reported a position in Intra-Cellular Therapies Inc. in Q3 2022 and held it in 7 quarters.
  • Front Row Advisors's Intra-Cellular Therapies Inc. position peaked at $9.2K in Q1 2024.
  • 355 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2024.

Based on Front Row Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.